Patrys preps for clinical trials of PAT-LM1

Patrys (ASX:PAB) has commenced clinical development for its second anticancer antibody, PAT-LM1, after the drug showed strong potential in blood cancers during lab trials.

The company has commenced the manufacturing process for a future clinical trial of PAT-LM1, an IgM antibody, after completing the cell line development for production.

During the most recent lab studies in blood cancers including leukaemias and lymphomas, PAT-LM1 showed strong and specific bindings to more than 90% of tested lymphoma cell lines and patient samples. These included some rare lymphoma types including marginal zone B-cell and Burkitt lymphoma.

The antibody also demonstrated an ability to induce cell death in mantle cell lymphoma and histiocytic lymphoma cells.

Patrys CEO Dr Marie Roskrow said the company is now planning for clinical trials.

“Currently, we anticipate that this antibody will be moved into clinical trial at the University of Würzburg where we will be working with the same clinicians who successfully executed the recent PAT-SM6 multiple myeloma trial,” she said.

PAT-LM1 has also shown promise in other cancer types including colon, lung, breast, ovary and pancreatic cancer.

Patrys (ASX:PAB) shares were trading 4.35% higher at $0.048 as of around 1 pm on Monday.